Severino tapped to helm Amgen's global development team

Amgen ($AMGN) has tapped Michael Severino, M.D., as its new senior vice president, global development and chief medical officer. Severino, 46, formerly vice president, global development at Amgen, is replacing Sean Harper, who was recently named executive vice president, R&D. "Mike brings broad experience and immense expertise to his new role and I am confident that under his leadership, Amgen's global development team will continue to deliver important new medicines for patients with serious illnesses," said Harper. Release

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.